Cortifenol H is classified within the therapeutic domain of corticosteroids, which are applied for their role in easing discomfort associated with inflammation across numerous organ systems. This class of medicine is commonly used across conditions presenting with acute episodes where supportive symptomatic management is appropriate, particularly those involving inflammatory or irritative processes. Cortifenol H is applicable across a wide range of therapeutic domains.

---

It supports patients during episodes of heightened discomfort by providing supportive relief for symptoms related to physical discomfort and systemic imbalance. This may include rheumatic disorders, certain allergic states where additional symptomatic support is needed, and specific gastrointestinal diseases like ulcerative colitis. In these clinical scenarios, the use of Cortifenol H assists with maintaining functional stability.

“It supports general well-being during symptomatic phases.”

Its use contributes to easing the overall symptom load, helping patients cope more steadily when symptoms become more noticeable.

---

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Cortifenol H (Chloramphenicol/Hydrocortisone ophthalmic) is restricted to specific patient populations as defined by regulatory labeling. Use is contraindicated and must be avoided by individuals with known hypersensitivity to any of its components. Due to the risks associated with Chloramphenicol, the medicine is also absolutely prohibited for patients with a personal or family history of blood dyscrasias, including aplastic anaemia, or those who previously experienced myelosuppression.

Because the product contains a corticosteroid, it is also contraindicated in cases of active viral diseases of the eye, such as epithelial herpes simplex keratitis, and fungal diseases of the ocular structures.

The medicine is not recommended for use during pregnancy and lactation, as the safety of topical use has not been established. While use is permitted for adults and children over two years, newborn infants require specific caution and potential dosage adjustment due to reduced systemic drug elimination. Furthermore, patients with pre-existing conditions like glaucoma or those who wear contact lenses must seek medical consultation prior to use.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cortifenol H (Chloramphenicol and Hydrocortisone) through formal restrictions and documented metabolic effects. The profile primarily identifies substances that are restricted due to additive toxicity or pharmacokinetic modification.

---

Interaction Classifications

Classification	Official Regulatory Statements
Contraindicated Combinations	Live or Live, Attenuated Vaccines; Drugs liable to suppress bone marrow function.
Mechanistic Basis	Inhibition of CYP2C19 and CYP3A4 isozymes; Additive toxicity.
Population-Specific Notes	Increased risk of accumulation in patients with impaired hepatic and/or renal function.

---

Officially Documented Outcomes

Co-administration with Live or Live, Attenuated Vaccines is formally contraindicated due to the potential for immunosuppressive effects from the Hydrocortisone component. The medicine is also restricted for concurrent use with drugs known to depress bone marrow function due to the risk of additive hematologic toxicity.

Regulatory information states that the Chloramphenicol component is a strong inhibitor of CYP3A4 and CYP2C19. This inhibition results in increased plasma concentrations of co-administered medicines that are substrates for these enzymes, including the immunosuppressants Tacrolimus and Cyclosporine, and the anti-epileptic Phenytoin. Conversely, concurrent use with hepatic enzyme inducers, such as Rifampicin, is associated with decreased serum concentrations of Chloramphenicol itself. No interactions with food, alcohol, or supplements are documented in official labeling.

Targeted Arrest of Bacterial Reproduction

The Chloramphenicol component engages a bacteriostatic mechanism by directly binding to the 50S ribosomal subunit within susceptible bacteria. This action specifically inhibits peptidyl transferase, which is the enzyme responsible for creating the long protein chains necessary for bacterial growth and division. By halting this core biosynthetic process, the drug arrests microbial proliferation, limiting the growth and reproduction of the microbial population.

---

Modulating the Host's Inflammatory Signaling Cascade

The second domain involves Hydrocortisone, which acts as an agonist on the intracellular Glucocorticoid Receptor (GR), leading to transcriptional modulation. This process up-regulates anti-inflammatory proteins that, in turn, inhibits Phospholipase A2 ( PLA2), thereby blocking the synthesis of potent mediators like Prostaglandins and Leukotrienes. This mechanism reduces the physiological processes of vascular leakage and cellular infiltration.

---

Complementary Biological Modulation

The two distinct mechanisms are complementary: one focuses on limiting microbial proliferation (via ribosomal inhibition), and the other focuses on modulating the inflammatory pathway (via receptor-mediated genetic suppression). This dual molecular strategy addresses both the microbial trigger and the host's physiological reaction. These complementary biological actions lead to the simultaneous control of microbial proliferation and the modulation of the inflammatory pathway.

Administration Guidelines

Cortifenol H (a combination of Chloramphenicol and Hydrocortisone) is applied using a standardized procedure for ophthalmic and otic care.

Administration Scope	Instruction
Route of Administration	Topical Ocular Use (Instillation into the Conjunctival Sac). Some formulations are also indicated for Topical Otic Use.
Dosing Schedule	Ointment: Apply a small amount, typically a strip of about 1 cm to 1.5 cm, into the lower conjunctival sac. Solution: Instill 1 to 2 drops.
Frequency Schedule	Initial: Apply every three hours (or more frequently) during the first 48 hours. Continuation: The interval between applications may be increased after the initial 48 hours.
Course Duration	Treatment should be continued for at least 48 hours after the eye appears normal. The total course of treatment should not typically exceed 10 days.
Age-Group Rules	Newborn/Infants: Dosage adjustment may be necessary due to reduced systemic elimination. Older Adults: No specific dose adjustment is generally required.

---

Procedural and Contextual Instructions

Standard instructions detail specific steps to ensure correct application and minimize contamination:

• Preparation: If using the ophthalmic solution (suspension), it must be shaken well before each use.
• Technique: To prevent contamination, do not allow the tip of the dropper or ointment tube to touch the eye, eyelid, or any other surface.
• Timing: If concurrently using other eye medications, an interval of at least 5 minutes must be observed between the application of Cortifenol H and the other product.
• Absorption: After instilling drops, gentle pressure may be applied to the nasolacrimal duct (inner corner of the eye) for 1 to 2 minutes to help reduce systemic absorption.
• Restriction: Contact lenses must be removed prior to application and should not be re-inserted for a specified period (typically 15 minutes), as stated in label information.

These guidelines establish the standardized, high-frequency, time-limited approach to the topical administration of Cortifenol H.

Research evidence / Overview of Studies for Cortifenol H

Evidence for Combination Use in Bacterial Ocular Infection

Research for the combination of active ingredients in Cortifenol H was studied for conditions associated with acute or disruptive episodes, specifically those involving bacterial infection alongside significant inflammation in the eye. The evidence base primarily involves short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The combination was studied alongside other treatments, including its single components (antibiotic or steroid alone) or a non-medicated treatment (placebo).

These trials focused on outcomes related to physical discomfort and changes in the severity of infection. Researchers monitored both the elimination of the bacterial pathogen (known as microbiological cure) and changes in signs of inflammation, such as redness and swelling. The findings describe patterns observed in the studies consistent with using a dual-action product that was studied for addressing both the microbial presence and the inflammatory response simultaneously over a short period. The evidence contributes to the broader evidence landscape regarding symptom patterns over the duration of an acute infection.

What is key to understand is that the evidence base includes extensive data for the individual components of the antibiotic and the steroid. However, comparative evidence is lacking in some areas regarding whether the fixed combination product was evaluated for superiority over the antibiotic alone for every patient presentation. Follow-up durations were limited to the period needed to resolve the acute infection, meaning that long-term patterns after the illness are not the focus of this primary research.

---

Evidence Focused on the Anti-inflammatory Component

The anti-inflammatory role of Cortifenol H was evaluated in studies focused on the hydrocortisone (corticosteroid) component. This research explored outcomes linked to inflammatory or irritative states in the anterior part of the eye, such as after certain surgical procedures or in specific inflammatory conditions. The trials evaluated objective changes, such as reductions in redness and swelling, as well as patient-reported outcomes describing perceived discomfort.

Research describes that topical steroids are studied for evaluating the symptoms of local inflammation. The data show patterns related to the localized immune response, which was the focus of the steroid ingredient's use. Studies report how symptoms evolved in the observed populations when the steroid component was applied in research contexts involving fluctuating or unstable symptoms of inflammation.

---

The Research Base for the Antibiotic Component

The foundational evidence for the Chloramphenicol component alone is derived from large-scale trials, built on large-scale, Randomized, Double-blind, Placebo-Controlled Trials. These studies research examined the outcomes of the antibiotic component in contexts of acute infective conjunctivitis in different age groups, including children and the general adult population.

---

Evidence Gaps and Long-Term Follow-up

Research focusing on the long-term effects of using Cortifenol H was observed in only a limited capacity. Due to the clinical considerations surrounding prolonged use of topical steroids, follow-up durations were limited in most primary trials. Therefore, long-term effects are not fully established for the fixed combination product. There is limited information for long-term outcomes regarding the durability of response or any impact on eye health over many months or years.

---

Studies in Specific Patient Populations

Data for certain groups remain insufficient. For instance, there is limited information on the use of the combination in pregnant or breastfeeding populations. While the principles of its use in older adults are consistent with general clinical practice, subgroup findings are uncertain when looking for specific, dedicated trials on the combination product in older individuals with multiple existing medical conditions.

Key Studies & References

1. Ophthalmic Antibiotic–Steroid Combinations Therapeutic Class Review (TCR)
2. Chloromycetin® Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) - DailyMed

Common questions about Cortifenol H (FAQ)

---

Q: What conditions is Cortifenol H most commonly prescribed for?

A: Official information indicates that Cortifenol H is indicated for use in ocular infections where the combined action of an antibiotic (Chloramphenicol) and an anti-inflammatory (Hydrocortisone) is appropriate. This covers infections and associated inflammation of the front surface structures of the eye.

---

Q: How long can a person safely use Cortifenol H continuously?

A: According to official regulatory documents, the total course of treatment should not typically exceed 10 days. The medicine must be continued for at least 48 hours after the affected area appears normal. Use beyond the recommended duration often requires close monitoring due to potential risks associated with the corticosteroid component.

---

Q: Can Cortifenol H cause skin thinning or discoloration?

A: Since Cortifenol H contains a topical corticosteroid, prolonged or excessive use has been associated with local effects like skin atrophy (thinning) and changes in skin color, such as hypopigmentation. The presence of these potential effects underscores the importance of following prescribed usage instructions.

---

Q: What should I do if I accidentally apply too much Cortifenol H?

A: Official labeling advises that increased systemic absorption can occur with prolonged or excessive use over large areas. If signs of excessive systemic absorption are noted, the prescribed course may need gradual reduction under medical supervision to monitor for potential effects like HPA axis suppression or Cushing's syndrome.

---

Q: Can Cortifenol H be used for bug bites or allergic reactions?

A: No. Official indications state that Cortifenol H is approved only for topical ocular (eye) and otic (ear) use involving infection and inflammation. It is not approved or indicated for general skin conditions like bug bites or rashes elsewhere on the body.

---

Q: Is Cortifenol H absorbed into the bloodstream?

A: Yes, systemic absorption of the medicine can occur after topical use. Official procedural instructions outline steps, such as applying pressure to the inner corner of the eye, intended to help reduce the amount of medicine absorbed.

---

Q: Is Cortifenol H safe for people with diabetes (general inquiry)?

A: The corticosteroid component requires caution in patients with diabetes mellitus. Corticosteroids may affect blood sugar levels, and regulatory documents suggest that caution and monitoring may be necessary for such patients.

---

Q: What is the typical duration of treatment with Cortifenol H?

A: The typical duration of a treatment course for Cortifenol H is up to 10 days. The medicine is usually prescribed for a short, acute episode and must be maintained for at least 48 hours after the infection or inflammation appears to have cleared.

---

Q: What's the difference between Cortifenol H and standard hydrocortisone cream?

A: Cortifenol H is a combination product that contains two active ingredients: the antibiotic Chloramphenicol and the corticosteroid Hydrocortisone. Standard hydrocortisone cream, by contrast, contains only the steroid. Cortifenol H is formulated to address both infection and inflammation simultaneously.

---

Q: What are the most common side effects people notice with Cortifenol H?

A: Common adverse reactions often occur at the site of application. These local effects may include sensations like burning, stinging, dryness, itching, and redness. If these local symptoms are severe or persistent, patients typically consult a healthcare provider.

---

Q: Is it normal to feel a stinging sensation when applying Cortifenol H?

A: Local effects such as a stinging or burning sensation have been reported as common adverse reactions at the application site for similar topical steroid products. This is generally considered a common local reaction.

---

Q: What happens if you stop using Cortifenol H suddenly?

A: If the medicine is stopped abruptly, especially after using it for an extended period, the corticosteroid component may lead to steroid withdrawal reactions or symptoms of adrenocortical insufficiency. Medical guidance usually involves gradual withdrawal if prolonged use has occurred, to mitigate these risks.

---

Q: Does Cortifenol H help with itching or just the inflammation?

A: The primary role of the corticosteroid component is to manage signs of inflammation, such as redness and swelling. However, official information notes that itching (pruritus) is a symptom that this class of medicine is used to manage.

---

Q: Is Cortifenol H considered a high, medium, or low-potency drug?

A: The hydrocortisone component in Cortifenol H is generally classified as a low-potency or mild topical corticosteroid in official potency charts.

---

Q: Why would a doctor prescribe Cortifenol H instead of an oral medication?

A: The antibiotic component, Chloramphenicol, is associated with a risk of serious blood disorders. This risk is generally considered lower with topical use than with oral administration, which is a key factor in choosing the topical route for localized infections.

---

Q: Can Cortifenol H be used multiple times a day?

A: Yes. Official guidelines permit multiple applications per day; for instance, the initial treatment schedule often involves frequent application during the first 48 hours.

---

Q: Are there any known withdrawal symptoms associated with stopping Cortifenol H?

A: Yes, official regulatory documents note that withdrawal from the corticosteroid component may be associated with symptoms of adrenal insufficiency or topical steroid withdrawal reactions, such as rebound redness or burning.

---

Q: Is it possible to have an allergic reaction to Cortifenol H?

A: Yes. The product is formally contraindicated (must not be used) in patients with a known hypersensitivity or allergy to any of the active substances or inactive ingredients in the formulation.

---

Q: Does the application frequency of Cortifenol H matter for its effectiveness?

A: Yes. The initial schedule requires the medicine to be applied more frequently during the first 48 hours. This increased frequency is important for achieving the desired therapeutic concentration of the medicine to control the condition.

Storage and Disposal of Cortifenol H

The required storage conditions for Cortifenol H vary by formulation, based on official regulatory documents for combination ophthalmic products.

Formulation	Unopened Storage Temperature	In-Use Stability
Ophthalmic Solution	Refrigerated (2 C to 8 C)	Discard 28 days after opening
Eye Ointment	Controlled Room Temperature (Below 25 C or 30 C)	Discard 4 weeks after opening

The solution must not be frozen and both forms must be protected from heat, light, and moisture. Store the medicine in its original, tightly closed container and keep out of the reach of children. Unused or expired Cortifenol H must be disposed of according to local pharmaceutical waste regulations and should not be discarded via wastewater or household trash.